Cisen Pharmaceutical Co., Ltd. (SHA:603367)

China · Delayed Price · Currency is CNY

14.13

+0.08 (0.57%)

Jul 29, 2026, 3:00 PM CST

-40.05% (1Y)

Market Cap	6.40B -34.1%
Revenue (ttm)	3.37B -10.1%
Net Income	408.45M -16.6%
EPS	0.90 -16.6%
Shares Out	452.75M
PE Ratio	15.69
Forward PE	n/a
Dividend	0.32 (2.28%)
Ex-Dividend Date	Jun 3, 2026

Volume	10,596,700
Open	14.00
Previous Close	14.05
Day's Range	14.00 - 14.25
52-Week Range	12.13 - 35.20
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Cisen Pharmaceutical

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company’s chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and analgesic drugs, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs, and hormonal dru... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1970

Employees 3,114

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603367

Full Company Profile

Financial Performance

In 2025, Cisen Pharmaceutical's revenue was 3.44 billion, a decrease of -13.48% compared to the previous year's 3.98 billion. Earnings were 421.25 million, a decrease of -17.22%.

Financial Statements